LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3713 | 4245 | 0.8770 | 0.8439 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3908 | 4245 | 0.9210 | 0.8999 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4054 | 4245 | 0.9551 | 0.9433 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4073 | 4245 | 0.9577 | 0.9445 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3721 | 4245 | 0.8766 | 0.8413 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1401 | 2060 | 4245 | 0.4850 | 0.2696 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4048 | 4168 | 0.9709 | 0.9624 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3569 | 4168 | 0.8565 | 0.8122 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3093 | 4168 | 0.7421 | 0.6540 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2742 | 4168 | 0.6578 | 0.5322 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2599 | 4168 | 0.6233 | 0.4803 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 72 | hr | 1401 | 1771 | 4168 | 0.4252 | 0.1607 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4725 | 4245 | 1.1140 | 1.1414 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4727 | 4245 | 1.1110 | 1.1335 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4822 | 4245 | 1.1351 | 1.1650 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4831 | 4245 | 1.1381 | 1.1695 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4741 | 4245 | 1.1176 | 1.1453 |
| SK-BR-3 | Nilotinib | 10 | uM | LJP5 | 72 | hr | 1401 | 2065 | 4245 | 0.4873 | 0.2740 |
| SK-BR-3 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3296 | 4168 | 0.7910 | 0.7228 |
| SK-BR-3 | JNK-9L | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3440 | 4168 | 0.8254 | 0.7701 |
| SK-BR-3 | JNK-9L | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3306 | 4168 | 0.7936 | 0.7264 |
| SK-BR-3 | JNK-9L | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1952 | 4168 | 0.4684 | 0.2344 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1163 | 4168 | 0.2791 | -0.1122 |
| SK-BR-3 | JNK-9L | 10 | uM | LJP6 | 72 | hr | 1401 | 1193 | 4168 | 0.2862 | -0.0976 |
| SK-BR-3 | PD0325901 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4003 | 4245 | 0.9422 | 0.9259 |